SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS)
KDUS 1.6000.0%Jul 2 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (69)2/11/2000 10:13:00 PM
From: scaram(o)uche  Read Replies (2) of 1833
 
Bioorg Med Chem Lett 1999 Aug 16;9(16):2413-8

Selective A1-adenosine receptor antagonists identified using yeast
Saccharomyces cerevisiae functional assays.

Campbell RM, Cartwright C, Chen W, Chen Y, Duzic E, Fu JM, Loveland M, Manning
R, McKibben B, Pleiman CM, Silverman L, Trueheart J, Webb DR, Wilkinson V, Witter
DJ, Xie X, Castelhano AL

Cadus Pharmaceutical Corporation, Tarrytown, NY 10591, USA.

Evaluation of a biased "library" of pyrrolo[2,3-d]pyrimidines using yeast-based functional assays
expressing human A1- and A2a-adenosine receptors, led to the A1 selective antagonist 4b. A
direct correlation between yeast functional activity and binding data was established. Practical
compounds with polar residues at C-4 of the pyrrolopyrimidine system required H-bond donor
functionality for high potency.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext